TICKERNERD
Menu
IFRXIFRXHealthcare · Biotechnology

IFRX Stock Forecast: InflaRx NV Price Predictions for 2026-2027

Last close, 14 Aug 2026
$2.04
+1.49% on the day

The 8 Wall Street analysts covering InflaRx NV hold a median 12-month price target of $8.53 — +318.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 9 of 100 as at 15 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$300.5M
Ticker Nerd rank
9 / 100
Median analyst target
$8.53
Analysts covering
8
Total return, dividends reinvested
1W
+10.9%
1M
+1.5%
YTD
+102.0%
1Y
+146.7%
From 52W high
−25.5%
From 52W low
+147.3%
$0.83
$2.74
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IFRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores InflaRx NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
9 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
80
Size
62
Revisions
55
Volatility
20
Value
13
Issuance
13
Growth
8
Accruals
8
Quality
2

Momentum (80): The shares have been drifting up relative to others.

Quality (2): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IFRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IFRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26IFRXHigh $14.06Median $8.53Low $3.01

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $3.01Median $8.53High $14.06

The green dot is the last close — the median target sits +318.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Aug 2026Cantor FitzgeraldMaintainsOverweight$4.00 → $6.00
13 May 2026Raymond JamesUpgradeStrong Buy$7.00 → $9.00
13 May 2026Raymond JamesUpgradeStrong Buy—
11 May 2026Cantor FitzgeraldMaintainsOverweight$2.00 → $4.00
11 May 2026Cantor FitzgeraldMaintainsOverweight—
11 May 2026HC Wainwright & Co.MaintainsBuy$6.00 → $8.00
11 May 2026HC Wainwright & Co.MaintainsBuy—
21 Apr 2026GuggenheimReiteratesBuy—
20 Mar 2026GuggenheimMaintainsBuy—
30 Dec 2025HC Wainwright & Co.ReiteratesBuy—
3 Dec 2025Leerink PartnersDowngradeMarket Perform—
10 Nov 2025GuggenheimMaintainsBuy—
2 Sept 2025HC Wainwright & Co.AssumesBuy$6.00
29 May 2025OppenheimerMaintainsOutperform—
8 May 2025OppenheimerInitiatesOutperform—
29 Apr 2025Cantor FitzgeraldInitiatesOverweight—
26 Mar 2025GuggenheimMaintainsBuy—
21 Mar 2025HC Wainwright & Co.ReiteratesBuy—
7 Mar 2025HC Wainwright & Co.ReiteratesBuy—
16 Jan 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IFRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

IFRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

InflaRx NV (IFRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.0×

Cheaper than 87% of US stocks

Price / sales
−29762.5×

Cheaper than 99% of US stocks

Price / book
1.8×

Cheaper than 50% of US stocks

EV / EBITDA
−4.0×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
−100.0%

Higher than 1% of US stocks

Gross margin
—
Operating margin
352965.0%

Higher than 99% of US stocks

Net margin
−24677.9%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−38.5%

Higher than 24% of US stocks

Return on assets
−18.5%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

IFRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IFRXInflaRx NV$300.5M
9
FATEFate Therapeutics, Inc.$298.8M
95
AVXLAnavex Life Sciences Corp.$298.4M
21
IRDOpus Genetics, Inc.$293.8M
50
VNDAVanda Pharmaceuticals, Inc.$308.5M
43
NMRANeumora Therapeutics, Inc.$291.3M
38
TRDAEntrada Therapeutics, Inc.$289.6M
51

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own InflaRx NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IFRX news & analysis

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

GlobeNewsWire · 6 Aug 2026positive

InflaRx announced its second quarter 2026 financial results and provided a business update. The company reported progress on izicopan for ANCA-associated vasculitis and select renal diseases, initiated a feasibility assessment for a broader European AAV strategy, released new preclinical data, and plans a PK bridging study in China late this year, with cash of €158.4 million expected to fund operations through 2029. A Virtual Capital Markets Day is planned for October 8, 2026.

Why it matters — The update details izicopan's clinical advancement, upcoming proof-of-concept milestones, and a cash runway through 2029, giving InflaRx investors clarity on near-term catalysts and financial staying power.

InflaRx to Report Second Quarter 2026 Results on August 6, 2026

GlobeNewsWire · 30 July 2026neutral

InflaRx announced it will release its second quarter 2026 financial and operating results on August 6, 2026, before the market opens. The company stated that no conference call is planned for the results.

Why it matters — The announcement informs shareholders of the scheduled release date for the company's quarterly financial performance and operational updates.

FAQ

Frequently asked questions about IFRX stock

What is the IFRX stock price forecast for 2026-2027?

The 8 Wall Street analysts covering InflaRx NV have a median 12-month price target of $8.53, with estimates ranging from $3.01 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IFRX stock a buy right now?

Of the 8 analysts covering InflaRx NV, 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks InflaRx NV 9 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IFRX?

As at 15 Aug 2026, InflaRx NV ranks 9 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (80 of 100).

Will IFRX stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +318.0% from the last close, and Ticker Nerd's factor model ranks InflaRx NV 9 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IFRX stock forecast for 2030?

No analyst covering InflaRx NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IFRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3.01 to $14 over the next 12 months.

How has IFRX stock performed over the past year?

InflaRx NV returned +146.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does InflaRx NV do?

InflaRx N.V. is a clinical-stage biopharmaceutical company developing innovative anti-inflammatory therapeutics by targeting the complement system, specifically the C5a pathway and C5aR receptor.

What is the latest news on IFRX?

The most recent item we track (GlobeNewsWire, 6 Aug 2026): "InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones". InflaRx announced its second quarter 2026 financial results and provided a business update. The company reported progress on izicopan for ANCA-associated vasculitis and select renal diseases, initiated a feasibility assessment for a broader European AAV strategy, released new preclinical data, and plans a PK bridging study in China late this year, with cash of €158.4 million expected to fund operations through 2029. A Virtual Capital Markets Day is planned for October 8, 2026.

Company

About InflaRx NV.

InflaRx N.V. is a clinical-stage biopharmaceutical company developing innovative anti-inflammatory therapeutics by targeting the complement system, specifically the C5a pathway and C5aR receptor. Headquartered in Jena, Germany, and founded in 2007, the company applies proprietary anti-C5a and C5aR technologies to discover and develop first-in-class or best-in-class inhibitors for treating life-threatening and debilitating inflammatory diseases. The company's lead program, vilobelimab, is a first-in-class monoclonal anti-C5a antibody designed to block inflammatory mediators while preserving the immune system's membrane attack complex defense mechanism. InflaRx's pipeline includes treatments for conditions such as pyoderma gangrenosum, severe COVID-19, cutaneous squamous cell carcinoma, and hidradenitis suppurativa. The company is also developing INF904, an orally available small molecule C5aR inhibitor targeting chronic inflammatory conditions. By selectively modulating the complement cascade rather than broadly suppressing immune function, InflaRx's approach aims to address multiple autoimmune and inflammatory diseases with improved safety profiles.

CEO Prof. Niels C. Riedemann M.D., Ph.D. · 65 employees · Germany · https://www.inflarx.de